1. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
   Serafino Fazio et al, 2023, BioMed CrossRef
2. Small molecules in the treatment of COVID-19
   Sibei Lei et al, 2022, Signal Transduction and Targeted Therapy CrossRef
3. The State-of-the-Art of Gene Editing and its Application to Viral Infections and Diseases Including COVID-19
   Yousef M. Hawsawi et al, 2022, Frontiers in Cellular and Infection Microbiology CrossRef
4. Niosomal formulation of mefenamic acid for enhanced cancer targeting; preparation, characterization and biodistribution study using radiolabeling technique
   Mona A. Shewaiter et al, 2023, Journal of Cancer Research and Clinical Oncology CrossRef
5. COVID-19 and Multiple Sclerosis: A Complex Relationship Possibly Aggravated by Low Vitamin D Levels
   William Danilo Fernandes de Souza et al, 2023, Cells CrossRef
6. NSAID: Current limits to prescription
   Theo Wirth et al, 2024, Joint Bone Spine CrossRef
7. Effects of Common Anti-Inflammatories on Adenovirus Entry and Their Physicochemical Properties: An In-Depth Study Using Cellular and Animal Models
   Hector R. Galvan-Salazar et al, 2024, Microbiology Research CrossRef
8. Renin–Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19
   Biwash Ghimire et al, 2023, Biomedicines CrossRef
9. A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients
   Carlo Brogna et al, 2024, Journal of Medical Virology CrossRef
10. NSAIDs, CGRP Monoclonal Antibodies, and COVID-19
    Berkay Alpay et al, 2023, Headache Disorders in Pandemic Conditions CrossRef